8-K: Intelligent Bio Solutions Surpasses 1,000 Installed Drug Screening Readers, Demonstrating Strong Growth

Intelligent Bio Solutions Inc. announced it has surpassed 1,000 installed drug screening readers, marking a significant milestone and demonstrating strong year-over-year growth in both reader and cartridge sales.

Summary

• Intelligent Bio Solutions Inc. (INBS) has achieved a major milestone, surpassing 1,000 installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024.
• The company sold 407 readers in the fiscal year ending June 30, 2024, a 26% increase compared to 323 readers sold in the previous fiscal year.
• The total number of installed readers reached 1,037 as of June 30, 2024, a 65% increase from 630 installed readers as of June 30, 2023.
• Cartridge sales also saw significant growth, with a 20% year-over-year increase from 67,575 cartridges in 2023 to 81,075 cartridges in 2024.
• The company is progressing towards FDA clearance, with the FDA provisionally determining that the cartridges are a Class II type device requiring a pre-market notification 510(k).

Sentiment

Score: 8

Explanation: The document conveys a very positive sentiment due to the significant growth in reader and cartridge sales, the achievement of a major milestone, and progress towards FDA clearance. The company's future outlook is also positive.

Positives

• The company has demonstrated strong growth in both reader and cartridge sales.
• The increase in installed readers indicates growing market demand for their non-invasive drug screening system.
• The repeat sales of cartridges create a robust and ongoing revenue stream.
• Progress towards FDA clearance is a positive step for future market expansion.
• The company is positioned for further expansion in the United States and internationally.

Risks

• The company's future success depends on obtaining FDA clearance for its drug screening system.
• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• The company's ability to realize commercial benefit from its partnerships and collaborations is not guaranteed.
• The company's ability to secure regulatory approvals is subject to risks and uncertainties.

Future Outlook

The company is positioned for further expansion, both in the United States and internationally, as it continues to lead the way in non-invasive drug testing technology. The company is also working towards FDA clearance for its drug screening system.

Management Comments

• Harry Simeonidis, President and CEO at INBS, stated that their growth remains strong as they continue to increase the number of new reader and cartridge sales year on year.
• Harry Simeonidis also commented that reaching over 1,000 installed readers is a major milestone that demonstrates an increasing awareness of and demand for their non-invasive drug screening system.
• Management stated that they remain committed to supporting their loyal and growing customer base as they proactively tackle common workplace issues associated with drug use.

Industry Context

The announcement highlights the growing demand for non-invasive drug testing solutions, reflecting a broader trend in workplace health and safety. The company's technology offers a quick and reliable alternative to traditional drug testing methods.

Comparison to Industry Standards

• While specific competitor data is not provided, the 65% year-over-year growth in installed readers and 20% growth in cartridge sales suggests a strong performance compared to industry averages for medical device companies in the drug testing sector.
• Companies like Abbott and Roche offer drug testing solutions, but Intelligent Bio Solutions focuses on non-invasive fingerprint technology, which is a differentiator.
• The 10-minute result time and 16-hour detection window are competitive advantages compared to traditional urine or blood tests, which can have longer turnaround times and detection windows.

Stakeholder Impact

• Shareholders will likely view the news positively due to the strong growth and achievement of a major milestone.
• Employees may be motivated by the company's success and growth.
• Customers will benefit from the company's innovative and reliable drug screening technology.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company will continue to expand its sales and marketing efforts.
• The company will continue to work towards FDA clearance for its drug screening system.
• The company will continue to support its growing customer base.

Key Dates

Keywords

drug screening, non-invasive, fingerprinting, FDA clearance, medical technology, workplace screening, cartridge sales, reader sales